The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages
- PMID: 9384235
- DOI: 10.1016/s0014-2999(97)01245-4
The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages
Abstract
Inducible nitric oxide synthase dependent production of nitric oxide (NO) plays an important role in inflammation. We investigated whether pristimerin ((20alpha)-3-hydroxy-2-oxo-24-nor-friedela-1(10),3,5,7-te traen-carboxylic acid-(29)-methylester), an antitumoral, antimicrobial as well as anti-inflammatory plant compound, has an effect on the inducible NO synthase system in lipopolysaccharide-activated RAW 264.7 macrophages. Pristimerin dose dependently (IC50: 0.2-0.3 microM) reduces nitrite accumulation, a parameter for NO synthesis, in supernatants of lipopolysaccharide-stimulated (1 microg/ml, 20 h) macrophages. This effect correlates with a reduced inducible NO synthase enzyme activity measured by conversion of [3H]L-arginine to [3H]L-citrulline and significantly lower levels of enzyme protein (Western blotting) in homogenates of cells cotreated with lipopolysaccharide and pristimerin (12 h). Northern blot analysis and polymerase chain reaction (PCR) showed decreased inducible NO synthase mRNA levels in activated macrophages exposed to pristimerin (4 h). Electrophoretic mobility shift assay (EMSA) demonstrated a markedly reduced binding activity of nuclear factor-kappa B (NFkappaB) in nuclear extracts of pristimerin-treated cells. These results suggest that pristimerin inhibits the induction of inducible NO synthase by a mechanism which involves inhibition of NFkappaB activation. This feature of pristimerin is likely to contribute to its anti-inflammatory activity.
Similar articles
-
Inhibition of the expression of inducible nitric oxide synthase and cyclooxygenase-2 in macrophages by 7HQ derivatives: involvement of IkappaB-alpha stabilization.Eur J Pharmacol. 2001 Apr 20;418(1-2):133-9. doi: 10.1016/s0014-2999(01)00922-0. Eur J Pharmacol. 2001. PMID: 11334875
-
Inhibition of lipopolysaccharide-inducible nitric oxide synthase, TNF-alpha and COX-2 expression by sauchinone effects on I-kappaBalpha phosphorylation, C/EBP and AP-1 activation.Br J Pharmacol. 2003 May;139(1):11-20. doi: 10.1038/sj.bjp.0705231. Br J Pharmacol. 2003. PMID: 12746218 Free PMC article.
-
Inhibitory effect of Buthus martensi Karsch extracts on interleukin-1beta-induced expression of nitric oxide (NO) synthase and production of NO in human chondrocytes and LPS-induced NO and prostaglandin E2 production in mouse peritoneal macrophages.Toxicol In Vitro. 2005 Sep;19(6):757-69. doi: 10.1016/j.tiv.2005.04.008. Toxicol In Vitro. 2005. PMID: 15963682
-
The multifaceted mechanisms of pristimerin in the treatment of tumors state-of-the-art.Biomed Pharmacother. 2022 Oct;154:113575. doi: 10.1016/j.biopha.2022.113575. Epub 2022 Aug 18. Biomed Pharmacother. 2022. PMID: 35988422 Review.
-
Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances.Front Oncol. 2021 May 7;11:671548. doi: 10.3389/fonc.2021.671548. eCollection 2021. Front Oncol. 2021. PMID: 34026649 Free PMC article. Review.
Cited by
-
Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2.Int J Oncol. 2014 May;44(5):1707-15. doi: 10.3892/ijo.2014.2325. Epub 2014 Mar 5. Int J Oncol. 2014. PMID: 24603988 Free PMC article.
-
Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer.Toxins (Basel). 2010 Oct;2(10):2428-66. doi: 10.3390/toxins2102428. Epub 2010 Oct 22. Toxins (Basel). 2010. PMID: 22069560 Free PMC article. Review.
-
Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.PLoS One. 2012;7(8):e43826. doi: 10.1371/journal.pone.0043826. Epub 2012 Aug 28. PLoS One. 2012. PMID: 22952775 Free PMC article.
-
Pristimerin Induces Apoptosis in Prostate Cancer Cells by Down-regulating Bcl-2 through ROS-dependent Ubiquitin-proteasomal Degradation Pathway.J Carcinog Mutagen. 2013 Nov 5;Suppl 6:005. doi: 10.4172/2157-2518.S6-005. J Carcinog Mutagen. 2013. PMID: 24877026 Free PMC article.
-
Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling.Oncol Lett. 2016 May;11(5):3111-3116. doi: 10.3892/ol.2016.4335. Epub 2016 Mar 16. Oncol Lett. 2016. PMID: 27123073 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources